"instanceType","uuid:ID","description","rationale","label","name","id"
"StudyDesign","5bb13715-e473-4306-9c5f-c03083fe8fe7","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","Study Design 1","StudyDesign_1"
